Cargando…

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells

Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Mengfan, Tian, Ye, Li, Wang, Li, Dan, Zhao, Tian, Yang, Yuxin, Li, Qiwen, Chen, Sujun, Yang, Yan, Zhang, Zhixiong, Tang, Liang, Liu, Zhonghua, Su, Bo, Li, Fei, Feng, Yonghong, Fei, Ke, Zhang, Peng, Zhang, Fan, Zhang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844726/ https://www.ncbi.nlm.nih.gov/pubmed/29552290 http://dx.doi.org/10.18632/oncotarget.24147

Ejemplares similares

Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib‐Resistant Non‐Small Cell Lung Cancer Cells
por: Li, Wang, et al.
Publicado: (2018)

G9A promotes tumor cell growth and invasion by silencing CASP1 in non-small-cell lung cancer cells
por: Huang, Tianhao, et al.
Publicado: (2017)

KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells
por: Kong, Lingzhi, et al.
Publicado: (2016)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
por: Han, Shuyan, et al.
Publicado: (2023)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

A TRIM71 binding long noncoding RNA Trincr1 represses FGF/ERK signaling in embryonic stem cells
por: Li, Ya-Pu, et al.
Publicado: (2019)

Exosome-derived circKIF20B suppresses gefitinib resistance and cell proliferation in non-small cell lung cancer
por: Wei, Si-Liang, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Zheng, Mao-hua, et al.
Publicado: (2016)

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015)

Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment
por: Xue, Cong, et al.
Publicado: (2015)

Knockdown of PLAT enhances the anticancer effect of gefitinib in non-small cell lung cancer
por: Yan, Mengnan, et al.
Publicado: (2020)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
por: Li, Jiajin, et al.
Publicado: (2016)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer
por: Yu, Wanjun, et al.
Publicado: (2021)

Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer
por: Liu, Shuliang, et al.
Publicado: (2016)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Relationship between miR-7 expression and treatment outcomes with gefitinib in non-small cell lung cancer
por: Mou, Kun, et al.
Publicado: (2016)

Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
por: Li, Guangda, et al.
Publicado: (2021)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways
por: Wu, Zhiqiang, et al.
Publicado: (2020)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer
por: Yang, R.F., et al.
Publicado: (2017)

Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer
por: Guan, Shaoxing, et al.
Publicado: (2020)

Gefitinib for asymptomatic brain metastasis from advanced non‐small cell lung cancer: Report of a favourable outcome
por: Liu, Wen‐Yang, et al.
Publicado: (2016)

Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
por: Han, Shu-Yan, et al.
Publicado: (2014)

Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Zhu, Xinhai, et al.
Publicado: (2016)

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status
por: Wei, Zhong, et al.
Publicado: (2008)

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018)

Gefitinib versus Docetaxel in Treated Non-small-cell Lung Cancer: A Meta-analysis
por: Wang, Bing, et al.
Publicado: (2017)

Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
por: Chen, Mu-Tong, et al.
Publicado: (2023)

The combination of MnO(2)@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer
por: Zhang, Jisong, et al.
Publicado: (2022)

Sequence-Dependent Antiproliferative Effects of Gefitinib and Docetaxel on Non-Small Cell Lung Cancer (NSCLC) Cells and the Possible Mechanism
por: Chen, Bei, et al.
Publicado: (2014)

Pharmacokinetic analysis of gefitinib in a patient with advanced non‐small cell lung cancer undergoing hemodialysis
por: Luo, Jinmei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vi810clbg80d2buadtmhrm21rf